Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DPP- Inhibitor · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DPP-IV Inhibitor | DRUG | Escalating doses po bid or qd |
| Placebo | DRUG | po bid or qd |
| Metformin | DRUG | As prescribed |
Inclusion Criteria: * adult patients 18-75 years of age; * type 2 diabetes diagnosed \>=1 month before screening; * no previous treatment, or previous treatment with no more than 2 oral medications. Exclusion Criteria: * type 1 diabetes; * type 2 diabetes treated with insulin or a PPAR gamma agon...
DPP- Inhibitor is an investigational small molecule being developed for the treatment of Diabetes Mellitus Type 2. It is currently in Phase 2 clinical development and has been studied in completed trials involving patients with Type 2 diabetes.
DPP- Inhibitor is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 diabetes.
DPP- Inhibitor is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, with a total of 509 participants enrolled.
DPP- Inhibitor has been studied in two completed Phase 2 trials: NCT00111631, which enrolled 218 patients, and NCT00111670, which enrolled 291 patients. Both trials were randomized, double-blind, placebo-controlled studies in patients with Type 2 diabetes.
DPP- Inhibitor is also referred to as DPP-IV Inhibitor in clinical trial records. The trials listed under NCT00111631 and NCT00111670 describe the drug as a DPP-IV Inhibitor, indicating that these names refer to the same investigational compound.